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Geographic variations in outcomes in patients with heart failure have been of great interest 
recently. Recent secondary analyses of clinical trials have suggested that geographic 
variation in outcomes in heart failure may be important for heart failure with preserved but 
not reduced ejection fraction (1,2). This has led to much discussion of the implications of 
conducting multinational clinical trials which take place in countries that are geographically 
distinct with differing health care systems (3,4). In contrast, the epidemiology of heart 
failure clearly varies by geographic region. It also varies within region by level of income of 
the individual countries (5). However, in contrast to clinical trials that hold data on many 
countries from all regions of the world, epidemiological data from many regions are still 
lacking. Data from Western Europe and North America predominate the literature. While 
data from other parts of Europe, Africa, the Middle East, Asia, Australasia/Pacific and 
Central/South America do exist (6-10), they are generally lacking by comparison. This has 
been due, in part, to the lack of infrastructure and large epidemiological datasets in many of 
these regions. However, with the increasing use of information technology in health care 
systems around the world, more and more data is being generated for the heart failure 
community to analyse and interpret. In the current issue of the European Journal of Heart 
Failure data from a national hospitalisation database in Slovenia provides a valuable insight 
into the epidemiology of heart failure in the relatively understudied area of Central Europe 
(11).  
 
In a study of hospitalisation rates for heart failure in Slovenia (a country with a population of 
just over 2 million people) Omersa and colleagues examine the rate of hospitalisation for 
heart failure and their trends between 2004 and 2012 (11). They report that the 
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standardised rate of hospitalisation for heart failure was much higher than has previously 
been described in other country level epidemiological datasets. As discussed by authors, this 
may in part be due to the older age of the Slovenian population, but it likely reflects other 
more complex differences. Potential explanations include admission thresholds and biases, 
reporting biases for the diagnosis of heart failure and differences in the availability of 
services such as heart failure nurse networks that can help reduce hospitalisations. Although 
no data on prescribed therapies was available, differences in the use of evidence based 
therapies and devices may further explain this discordance in hospitalisation rates. It may be 
easy to conclude that altering health care systems or additional interventions might change 
these rates, but it must be recognised that what is found to be effective in one region may 
not be as easy to institute or effective in another region (or even within a region) (12). 
Understanding the local epidemiology of heart failure and the underlying causes behind the 
trends is therefore crucial before embarking on changes to a health care system.  
 
In an effort to explain the trends observed, Omersa et al (11) present data on the 
distribution of comorbidities and their associations with outcomes. It is not surprising that 
the burden of comorbidities was high, nor that comorbidities were associated with higher 
hospitalisation rates and mortality. However, the distribution of comorbidities was very 
different to many of the prior epidemiological studies. Rates of ischaemic heart disease 
were generally lower, and hypertension higher, than prior studies from elsewhere in 
Europe. This may represent a markedly different distribution of the risk factors and 
aetiology of heart failure in Central as opposed to Northern Europe (5). The data from 
Omersa et al are not outliers either. The EuroHeart survey described a gradation in the 
prevalence of comorbidities from East to West Europe (13). This would certainly fit with 
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position Slovenia occupies within Europe, with rates of ischaemic heart disease in keeping 
with its neighbours to the west, but lower than that of countries to the east. Or it may 
simply reflect a survival bias; those with ischaemic heart disease in Slovenia may not live 
long enough to develop heart failure. While the data should always be examined for 
potential explanations for differences with the published literature, it is not always easy. 
Given the broad number of potential aetiologies and risk factors, identifying, tracking and 
interpreting trends in these other factors using other data sources, is necessary to fully 
understand the epidemiology of heart failure in a region. 
 
It is important to acknowledge the role that comorbidities play in the burden of heart 
failure. The crude numbers are perhaps the most interesting aspect of the study. In the 
database of hospitalisations there were 2.4 million hospitalisations. Hospitalisations where 
heart failure was the primary cause of admission accounted for 2% of these admissions and 
readmissions for heart failure did not change over time. Hospitalisations in patients with 
heart failure for non-heart failure reasons i.e. due to comorbid diagnoses, accounted for 4% 
of hospitalisations and these readmissions increased over the study period. Therefore, 
approximately 6% of all hospitalisations in the country were due to heart failure or occurred 
in a patient with heart failure. This is possibly due to the higher burden of comorbidities in 
patients with heart failure but also improvements in survival and the removal of the 
competing risk of death. Whatever the underlying reason it is clear that the burden of ill 
health that these patients carry and place on the health care system in Slovenia, is huge. 
 
Understanding the epidemiology of heart failure in countries outside of Western Europe 
and North America is important. While data are influenced by local factors, any data has 
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implications for the wider region from which the data are derived and regions across the 
world. As more clinical trials are conducted in more areas of the world, data are needed to 
help plan recruitment and estimate potential event rates. Although we may seek to remove 
or minimise geographic variation in clinical trials, in epidemiological studies we should 
embrace such differences. As long as we take time to understand these differences they 
present local and international clinicians with an opportunity to further the understanding 
of a disease that still exerts a heavy burden on individuals and health care systems.  
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